Devyser’s hereditary breast and ovarian cancer (HBOC) test has received a CE mark from the European Commission and is now approved as a diagnostic test for both cancers in Europe. The CE mark is a certification for products sold in the European Economic Area to indicate the product has met all legal standards, and has been evaluated to meet all safety, health, and environmental regulations. The test, which is based on the company’s patented next-generation sequencing (NGS) library preparation…
You must be logged in to read/download the full post.
The post Devyser’s Gene Screening Test for Breast, Ovarian Cancers Approved in Europe appeared first on BioNewsFeeds.